# Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients

> **NCT06593197** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Dow University of Health Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Vitiligo

## Interventions

- **COMBINATION_PRODUCT:** Apremilast with NB-UVB
- **DEVICE:** NB-UVB

## Key facts

- **NCT ID:** NCT06593197
- **Lead sponsor:** Dow University of Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-01-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06593197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06593197, "Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06593197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*